TL;DR: The Centers for Medicare & Medicaid Services modified NCD 198, the National Coverage Determination governing cytogenetic studies, effective March 7, 2026. Here's what billing teams need to do.
CMS cytogenetic studies coverage policy under NCD 198 Medicare covers chromosome analysis when the test is reasonable and necessary for five specific conditions. This policy does not list specific CPT or HCPCS codes in the current version—but the covered indications are tightly defined, and claims falling outside those indications will deny. If your lab, hematology, or genetics practice bills Medicare for cytogenetic studies, this update deserves your attention before the effective date of March 7, 2026.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | CMS (Centers for Medicare & Medicaid Services) |
| Policy | Cytogenetic Studies — NCD 198 |
| Policy Code | NCD 198 |
| Change Type | Modified |
| Effective Date | 2026-03-07 |
| Impact Level | Medium |
| Specialties Affected | Clinical Laboratory, Hematology/Oncology, Genetics, Maternal-Fetal Medicine, Pathology |
| Key Action | Audit all Medicare cytogenetic study claims to confirm the ordering diagnosis maps directly to one of NCD 198's five covered indications |
CMS Cytogenetic Studies Coverage Criteria and Medical Necessity Requirements 2026
NCD 198 is the National Coverage Determination governing Medicare coverage of cytogenetic studies—the microscopic examination of human chromosomes. CMS defines the service narrowly: chromosome analysis is a diagnostic test, not a screening tool, and Medicare pays only when the test is reasonable and necessary for a covered condition.
The CMS cytogenetic studies coverage policy covers five indications. Each one requires that the test is being used for diagnosis or treatment of the condition—not for general population screening or research. Medical necessity is the threshold, and it has to be documented in the medical record before the claim goes out.
The five covered indications are:
| # | Covered Indication |
|---|---|
| 1 | Genetic disorders in a fetus — including the policy's example of mongolism (Down syndrome). This is tied to Medicare Benefit Policy Manual, Chapter 15, §20.1. Prenatal cytogenetic testing on a Medicare beneficiary is covered when there's a documented clinical indication in the fetus. |
| 2 | Failure of sexual development — conditions where chromosomal analysis is needed to establish or clarify the diagnosis. |
| 3 | Chronic myelogenous leukemia (CML) — cytogenetics is a standard diagnostic and monitoring tool for CML, and Medicare coverage aligns with that clinical reality. |
| 4 | Acute leukemias — specifically lymphoid (FAB classifications L1, L2, L3), myeloid (FAB classifications M0 through M7), and unclassified acute leukemias. |
| 5 | Myelodysplasia — including myelodysplastic syndromes where chromosomal analysis informs diagnosis and treatment planning. |
The real issue for billing teams is documentation. CMS requires the diagnosis to be present and clinically supported. A claim for cytogenetic studies on a patient with an unrelated hematologic condition—or with no supporting diagnosis documented—will fail medical necessity review.
This policy does not mention prior authorization as a requirement. But absence of a prior auth requirement doesn't mean claims process automatically. Medical necessity documentation is still your first line of defense against a claim denial.
On reimbursement: NCD 198 does not set a fee schedule or rate—it establishes coverage. Reimbursement rates for cytogenetic procedures are determined by the Clinical Laboratory Fee Schedule (CLFS). Check the CLFS for the specific procedure codes you bill.
Coverage Indications at a Glance
| Indication | Coverage Status | Notes |
|---|---|---|
| Genetic disorders in a fetus (e.g., Down syndrome) | Covered | Must be reasonable and necessary; see Medicare Benefit Policy Manual, Chapter 15, §20.1 |
| Failure of sexual development | Covered | Chromosomal analysis must be clinically indicated for diagnosis |
| Chronic myelogenous leukemia (CML) | Covered | Standard use for diagnosis and monitoring |
| Acute leukemia — lymphoid (FAB L1, L2, L3) | Covered | Must document specific FAB classification in the record |
| Acute leukemia — myeloid (FAB M0 through M7) | Covered | Must document specific FAB classification in the record |
| Acute leukemia — unclassified | Covered | Unclassified acute leukemia is explicitly included |
| Myelodysplasia | Covered | Covers myelodysplastic syndromes where cytogenetics informs treatment |
| Cytogenetic studies for conditions not listed above | Not Covered | No coverage outside the five listed indications under NCD 198 |
| Screening without a specific covered diagnosis | Not Covered | Reasonable and necessary standard requires a documented, covered clinical indication |
CMS Cytogenetic Studies Billing Guidelines and Action Items 2026
The modification to NCD 198 went into effect March 7, 2026. If you haven't already reviewed your charge capture and documentation requirements against the updated policy, do it now.
| # | Action Item |
|---|---|
| 1 | Audit your active Medicare cytogenetic study claims against the five covered indications. Pull claims from the last 90 days and confirm each one maps to a genetic disorder in a fetus, failure of sexual development, CML, acute leukemia (with FAB classification), or myelodysplasia. Any claim tied to a different diagnosis is a denial risk. |
| 2 | Confirm FAB classifications are documented in the medical record for acute leukemia cases. NCD 198 is specific—it names FAB L1, L2, L3 for lymphoid and M0 through M7 for myeloid. If the ordering physician's documentation says "acute leukemia" without a FAB subtype, your claim may not satisfy medical necessity review. Push back to the ordering provider before the claim leaves your system. |
| 3 | Update your internal cytogenetic studies billing guidelines to reflect the covered indications list. Train your coding team on the exact five conditions. Post the list where coders can reference it during charge entry. This is a short list—five conditions—and there's no excuse for billing outside it. |
| 4 | Check for MAC-level local coverage determinations (LCDs) that may add requirements on top of NCD 198. National coverage determinations set the floor. Your Medicare Administrative Contractor may have issued an LCD with additional documentation requirements or billing instructions for cytogenetic studies in your region. Log into your MAC's portal and search for policies that cross-reference NCD 198 or cytogenetic testing. |
| 5 | Map your ICD-10-CM codes to the covered indications before billing. NCD 198 does not list specific diagnosis codes, which means your team needs to make the mapping. For CML, that's typically Z-codes or C91–C95 range codes. For myelodysplasia, look at D46 codes. For acute leukemias with FAB classifications, confirm your ICD-10 code captures the specific subtype. If you're not sure how your diagnosis mix maps, talk to your compliance officer before billing under this updated policy. |
| 6 | Don't assume no prior authorization means no scrutiny. NCD 198 doesn't require prior auth, but post-payment audits on cytogenetic studies are common. The medical record needs to show why the test was ordered, what condition it was meant to diagnose or treat, and how the result was used. Gaps in that documentation chain create audit exposure. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Cytogenetic Studies Under NCD 198
NCD 198 does not list specific CPT or HCPCS codes. This is worth calling out because it creates a documentation and coding burden for your team.
Without a code list in the NCD itself, your coders have to apply clinical judgment and reference the Clinical Laboratory Fee Schedule to identify the correct cytogenetic procedure codes. The policy covers the service category—chromosome analysis—not a discrete list of codes. That means the medical necessity determination depends entirely on the documented indication, not the code itself.
No Specific Codes Listed in NCD 198
| Field | Detail |
|---|---|
| CPT/HCPCS Codes | Not specified in NCD 198 |
| ICD-10-CM Codes | Not specified in NCD 198 |
| Code Source | Reference the Clinical Laboratory Fee Schedule and your MAC's LCD for applicable codes |
What This Means for Your Coding Team
Because the policy doesn't enumerate codes, your team needs to cross-reference:
- The Clinical Laboratory Fee Schedule (CLFS) for cytogenetic procedure codes and reimbursement rates
- Your MAC's LCD for any region-specific code lists tied to cytogenetic studies
- ICD-10-CM diagnosis codes that precisely capture one of the five covered indications—with appropriate specificity for leukemia FAB classifications and fetal genetic conditions
This is not a situation where you can rely on the NCD alone to build your charge capture. The absence of a code list in the coverage policy is a gap your billing team has to fill with external references.
If your team bills cytogenetics frequently, build a crosswalk document that ties each of the five covered indications to the ICD-10-CM codes you use in practice. Then confirm those diagnosis codes are present on every claim. That crosswalk is your first line of defense in an audit.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.